M&A / Deals Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation Pharmaceutical Business ReviewBofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan Lee.M&A / DealsMetabolic & GLP-1Read full story pharminent April 10, 2026 (Last updated: April 10, 2026) Pharmaceutical Business Review Bofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan Lee. M&A / DealsMetabolic & GLP-1Read full story Post navigation Previous: Precision Medicine in Early Oncology Trials: Biomarkers as Strategic DriversNext: Roche and C4 Therapeutics to advance degrader-antibody conjugates research Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
